Germany’s DZNE launched NeuroGenomeHub, a new brain genomics initiative funded with about €6 million to build a global genome database for neurodegenerative diseases. The project aims to sequence samples from roughly 25,000 individuals over two years, using samples drawn from ongoing DZNE studies, including the Rhineland study. DZNE said the initiative will leverage multiple sample types, long-read sequencing, and DNA methylation analysis to enrich the database for insights into disease risk and progression. Scientific director Joachim Schultze described the goal as enabling new diagnostics, prevention approaches, and therapy pathways by identifying genome features tied to neurodegenerative outcomes. For the genomics ecosystem, the effort is another push toward large-scale multi-omic resources that can feed biomarker discovery and patient stratification strategies across the neurodegeneration pipeline.